AGI-134 is under clinical development by BioLineRx and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II drugs for Endometrial Cancer have a 22% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AGI-134’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AGI-134 overview

AGI-134 is under development for the treatment of solid tumors, metastatic colorectal cancer, head and neck cancer squamous cell carcinoma and metastatic melanoma, melanoma, breast cancer, squamous cell carcinoma, Sarcomas, Cervical Cancer, Endometrial Cancer and synovial sarcoma The drug candidate is administered through an intratumoral route. It is a fully synthetic alpha-Gal (Gala1-3Galb1-4GlcNAc-R) glycolipid. The drug candidate is developed based on Alphaject technology.

BioLineRx overview

BioLineRx is a clinical-stage biopharmaceutical company that focuses on the development of products related to cancer and immunology. Its pipeline product BL-8040 is for the treatment of acute myeloid leukemia (AML), and relapsed or refractory AML. The company’s other pipeline drug candidate AGI-134 is synthetic alpha-gal immunotherapy that finds application in the treatment of solid tumors. BioLineRx‘s only product BL-5010 is a novel medical device indicated for the non-surgical removal of skin lesions. BioLineRx is headquartered in Modi’in-Maccabim-Re’ut, Israel.

For a complete picture of AGI-134’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.